Latest News/Press

CLEO COVID-19 KAP Community Study – Press Release

The COVID-19 pandemic has presented unique, unprecedented challenges for national healthcare systems. The faltering global response - characterized by a lack of preparedness among health care institutions, workers and the wider community - has underscored the importance of investing in public health research. However, it has also provided a unique opportunity for countries to diagnose and treat gaps within their own capacity for disease prevention. 

Like other countries, Greece has turned to urgent measures such as social distancing, quarantining, travel restrictions and border closures to rapidly halt transmission, reduce the risk of illness and protect healthcare systems from overfilling. Public misconceptions about transmissible diseases play a large part in adherence to these measures, and in the case of COVID, may have prevented the most effective response to the pandemic.

Latest Publications

POTENTIAL BENEFIT FROM THE IMPLEMENTATION OF THE KAISER PERMANENTE NEONATAL EARLY-ONSET SEPSIS CALCULATOR ON CLINICAL MANAGEMENT OF NEONATES WITH PRESUMED SEPSIS

Kopsidas I, Molocha NM, Kourkouni E, Coffin S, Gkentzi D, Chorianopoulou E, Dimitriou G, Kapetanaki A, Karavana G, Lithoxopoulou M, Polychronaki M, Roilides E, Triantafyllidou P, Triantafyllou C, Tsopela GC, Tsouvala E, Tsolia MN, Zaoutis T, Spyridis N; PHiG Investigators: Vassiliki Papaevangelou, Asimina Tsintoni, Vasiliki Soubasi-Griva, Marianna Skordala-Riti, Maria Theodoraki.

Eur J Pediatr., 2021 Oct, DOI: https://doi.org/10.1007/s00431-021-04282-x

Abstract

Aim: To assess the potential benefit from the implementation of the Kaiser Permanente early-onset sepsis calculator (EOS-C), in terms of antibiotic use and requested laboratory tests, in a network of neonatal intensive care units (NICUs) in Greece, and to determine the incidence of early-onset sepsis (EOS) in Greek NICUs, a prospective surveillance study was conducted in 7 NICUs between April 2018 and June 2019.
Methods: Data were collected for all newborns ≥ 34 weeks’ gestation receiving empiric antibiotic therapy within the first 3 days of life. The number of live births and positive blood or cerebrospinal fluid cultures within the first 3 days of life were used for calculation of EOS incidence. Evaluation of possible impact of implementing the calculator was done by comparing the clinicians’ recorded management to the calculator’s suggested course of action.